ClinicalTrials.gg
CompletedNCT01166542Updated Nov 5, 2014

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

A Phase 3 interventional study of REOLYSIN and Carboplatin in Carcinoma, Squamous Cell of the Head and Neck, sponsored by Oncolytics Biotech. Completed at 77 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-05.

Sponsored by Oncolytics Biotech · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Enrollment
163rd of 993
167 · median 41
Started
2010
with 29 others
Phase 3
71 of 1,099
12 open now
Registered
256th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 163rd largest by enrollment of the 993 interventional ones that give a count, is one of 30 that started in 2010, is one of 71 in phase 3, and was the 256th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.

Read the detailed description

Squamous cell carcinoma of the head and neck is the sixth most common cancer in the world. More than 50% of patients diagnosed with advanced regional disease will relapse locally or at distant sites. Initial therapeutic options include irradiation, surgery and chemotherapy. The most commonly used agents are cisplatin and carboplatin, generally in combination with 5-FU or a taxane. Erbitux has been approved for use in first-line with radiation and in second-line as monotherapy. Only about a third of the patients will respond to first-line platinum-based therapy and the median overall survival is about 6-9 months.

Preliminary assessment of a Phase 1-2 study conducted in the UK investigating the combination of REOLYSIN, carboplatin and paclitaxel suggested that patients with head and neck carcinomas may represent a group of patients in whom this treatment combination is active. Studies have also shown that paclitaxel and carboplatin combination therapy may be effective in head and neck cancers, even in heavily pretreated patients and those resistant to previous treatment. These results strongly support the utility of the carboplatin/paclitaxel combination as a control arm for salvage therapy in platinum refractory patients, a patient group with few and poor treatment options and with no gold standard therapy.

This Phase 3 study is designed to compare response rates following intravenous administration of REOLYSIN (Reovirus Type 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.

Overall survival is a primary endpoint of this trial. Patients will be clinically evaluated after each course of treatment and radiologically every 6 weeks on and after treatment. The safety of the paclitaxel and carboplatin with intravenous blinded placebo or intravenous blinded REOLYSIN will also be assessed.

03

Conditions studied

  • Carcinoma, Squamous Cell of the Head and Neck

Keywords

  • carcinoma
  • squamous cell
  • head
  • neck
  • REOLYSIN (Reovirus Type 3 Dearing)
  • chemotherapy
  • Carboplatin
  • Paclitaxel
  • metastatic
  • recurrent
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Each patient MUST:

  • have recurrent or (R/M) confirmed squamous cell carcinoma (SCC) of the head and neck (oropharynx, oral cavity, larynx, hypopharynx) or squamous cell nasopharynx cancer (NPC) with distal metastasis(es) and no secondary cancers (Patients with NPC without distal metastasis(es) or with undifferentiated NPC are not eligible).
  • have at least one lesion that is measurable by computed tomography or magnetic resonance imaging (Lesions persisting in previously treated radiation fields are considered not evaluable for response except if representing a relapse in a mucosal or nodal lesion that previously demonstrated a complete response. Any new lesion within the previous radiation fields is acceptable for determination of response and/or progression).
  • have completed chemotherapy for R/M SCCHN which progressed on or within 190 days following the completion of platinum or platinum-based chemotherapy.
  • have no continuing acute toxic effects (except alopecia) of any prior radiotherapy, chemotherapy, or surgical procedures. Any surgery involving the SCC for which the patient is being treated (except ) must have occurred at least 28 days prior to study enrollment.
  • have received no chemotherapy, radiotherapy, immunotherapy or hormonal therapy within 28 days.
  • have Performance Score of ≤ 2.
  • have of at least 3 months.
  • (ANC)≥ 1.5 x 10\^9/L ; ≥100 x 10\^9/L]; ≥9.0 g/dL; serum creatinine ≤1.5 xULN; ≤1.5 x ; /ALT ≤2.5 x ULN.
  • negative pregnancy test for females with .
  • Be wiling and able to comply with scheduled visits, the treatment plan, and laboratory tests.

Exclusion Criteria: No patient may:

  • receive concurrent therapy with any other anticancer agent while on study.
  • have been treated with a taxane for SCCHN.
  • have current -- or with a history of -- because of their poor prognosis and because of the frequent development of progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • be on chronic therapy or have known infection or active or C.
  • be a pregnant or breast-feeding woman. Female patients of childbearing potential must agree to use effective , be surgically sterile, or be . Male patients must agree to use effective contraception or be surgically sterile. Barrier methods are a recommended form of contraception.
  • have cardiac disease (, Class III or IV) including, but not limited to, pre-existing arrhythmia, uncontrolled angina pectoris, or myocardial infarction within 1 year prior to study entry.
  • have dementia or any altered mental status that would prohibit .
  • have any other acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the Principal Investigator, would make the patient inappropriate for this study.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
167 participants (actual)

Study arms

  • Active comparator
    REOLYSIN, paclitaxel, carboplatin

    Biological: REOLYSIN · Drug: Carboplatin · Drug: Paclitaxel

  • Placebo comparator
    placebo, paclitaxel, carboplatin

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Placebo

Interventions

  • BiologicalREOLYSIN

    3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle

    Also known as: reovirus serotype 3 Dearing Strain

  • 5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle

  • 175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time frame: every 3 months until death.

Secondary outcomes

  1. Progression-free survival

    Time frame: Assessed every 6 weeks until disease progression or death.

  2. Objective response (complete response (CR) + partial response (PR)) rate and duration

    Time frame: Evaluation of response is conducted every 6 weeks on and after study. Duration of objective response is measured from the time measurement criteria are first met for CR or PR until recurrent or progressive disease is objectively documented.

  3. Number of participants with adverse events as a measure of safety and tolerability of REOLYSIN when administered in combination with paclitaxel and carboplatin.

    Time frame: Within 30 days of the last dose of REOLYSIN.

  4. Compare Best % Tumor Specific Response in loco-regional disease and/or metastatic disease for the treatment regimens in the study population

    Time frame: Assessed every 6 weeks until disease progression or death.

07

Study locations

77 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Arizona Oncology Associates
    Tucson, Arizona 85715, United States
  • Providence Health and Services
    Burbank, California 91505, United States
  • Wilshire Oncology Medical Group
    Corona, California 92879, United States
  • BMS Physician Practice, A Medical Corporation DBA Medical Oncology Care Associates
    Orange, California 92868, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Pasco Hernando Oncology Associates, PA
    New Port Richey, Florida 34652, United States
  • Emory University - Winship Cancer Institute
    Altanta, Georgia 30322, United States
  • Alexian Brothers Hospital Network
    Elk Grove Village, Illinois 60007, United States
  • Mary Bird Perkinds Cancer Center - Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 59169, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Case Comprehensive Cancer Center, University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Mercy Cancer Center
    Toledo, Ohio 43623, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Oncology- Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Cancer Therapy and Research Center at UTHSCSA
    San Antonio, Texas 78229, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Columbia Basin Hematology and Oncology
    Kennewick, Washington 99336, United States
  • ZNA Middelheim
    Antwerpen, Belgium
  • University Hospital Antwerp
    Edegem, Belgium
  • Universitair Ziekenhuis Brussel
    Jette, 1090, Belgium
  • Tom Baker Cancer Centre
    Calgary, Alberta T2N 4N2, Canada
  • Juravinski Cancer Center
    Hamilton, Ontario L8V 5C2, Canada
  • London Health Sciences Centre
    London, Ontario N6A 4L6, Canada
  • Hopital Notre-Dame
    Montreal, Quebec H2L 4M1, Canada
  • Hopital Saint-André / Service d'Oncologie-Radiothérapie
    Bordeaux, 33075, France
  • Centre Antoine Lacassagne / Oncologie Médicale
    Nice, 06189, France
  • Institut Curie / Département d'Oncologie Médicale
    Paris, 75248, France
  • UKE Hamburg
    Hamburg, Germany
  • Attikon University Hospital
    Athens, Greece
  • Fovarosi Onkormanyzat Uzsoki Utcai Kórház
    Budapest, Hungary
  • Orszagos Onkologiai Intezet
    Budapest, Hungary
  • Pecsi Tudomanyegyetem
    Pecs, Hungary
  • Szegedi Tudományegyetem
    Szegedi, Hungary
  • Markusovszky Korhaz
    Szombathely, Hungary
  • Ufficio Sperimentazioni Cliniche c/o S.C. Oncologia Medica
    Cuneo, Italy
  • Fondazione IRCCS Istituto Nazionale del Tumori
    Milan, Italy
  • Ospedale San Paolo - Oncologia Medica
    Milan, Italy
  • University Hospital in Modena
    Modena, Italy
  • Centrum Onkologii - Instytyt im.M.Skłodowskiej-Curie
    Krakow, Poland
  • Szpital MSWiA - Centrum Onkologi
    Olsztyn, Poland
  • Wielkopolskie Centrum Onkologii
    Poznań, Poland
  • Wojewódzki Szpital Specjalistyczny im. M.Kopernika
    Łódź, Poland
  • State Health Care Institution "Arkhangelsk Regional Clinical Oncology Dispensary"
    Arkhangelsk, Russian Federation
  • Regional State Health Care Institution "Belgorod Oncology Dispensary"
    Belgorod, Russian Federation
  • State Health Care Institution "Chelyabinsk Regional Oncology Dispensary"
    Chelyabinsk, Russian Federation
  • State Health Care Institution "Republican Clinical Oncology Dispensary of Ministry of Health of the Republic of Tatarstan"
    Kazan, Russian Federation
  • State Budgetary Health Care Institution "Clinical Oncology Dispensary #1" of Krasnodar Region Health Care Department
    Krasnodar, Russian Federation
  • Regional Budgetary Health Care Institution "Kursk Regional Oncology Dispensary" of Health Care Committee of Kursk region
    Kursk, Russian Federation
  • Federal State Budgetary Institution "Medical Research Radiology Center" of Ministry of Public Health and Social Development of Russian Federation, Obninsk
    Obninsk, Russian Federation
  • Federal State Budgetary Institution "Russian Research Centre of Radiology and Surgery technologies" of Ministry of Public Health and Social Development of the Russian Federation
    Saint Petersburg, Russian Federation
  • Federal State Budgetary Institution "N. N. Petrov Oncology Research Institute" of Ministry of Public Health and Social Development of the Russian Federation
    Saint-Petersburg, Russian Federation
  • St.Petersburg State Health Care Institution City Clinical Oncology Dispensary"
    Saint-Petersburg, Russian Federation
  • State Health Care Institution "Oncology Dispensary №2" of Krasnodar Region Health Care Department
    Sochi, Russian Federation
  • State Health Care Institution "Tula Regional Oncology Dispensary"
    Tula, Russian Federation
  • State Budgetary Healthcare Institution "Republic Clinical Oncology Dispensary Ministry of Health of Bashkortostan"
    Ufa, Russian Federation
  • State Budgetary Health Care Institution of the Yaroslavl region "Regional Clinical Oncological Hospital"
    Yaroslavl, Russian Federation
  • Institute of Oncology Ljubljana
    Ljubljana, Slovenia
  • Hospital Vall D'Hebron
    Barcelona, 08035, Spain
  • Instituto Catlan de Oncologia (ICO) - Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, Spain
  • Hospital Santa Creu I Sant Pau
    Barcelona, Spain
  • Instituto Catlan de Oncologia (ICO) - Hospital Germans Trias I Pujol
    Barcelona, Spain
  • Hospital de Basurto
    Bilbao, Spain
  • Hospital de Navarra
    Pamplona, Spain
  • Beatson West of Scotland Cancer Center
    Glasgow, G12 0YN, United Kingdom
  • Royal Surrey County Hospital
    Guildford, GU2 7WG, United Kingdom
  • St. James's University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Guy's and St. Thomas Hospital
    London, SE1 9RT, United Kingdom
  • The Royal Marsden Cancer Center, Fulham Road branch
    London, SW3 6JJ, United Kingdom
  • The Royal Marsden Cancer Center, Sutton Branch
    Sutton, SM2 5PT, United Kingdom
  • Musgrove Park Hospital
    Taunton, TA1 5DA, United Kingdom
  • The Velindre Hospital
    Whitchurch, CF14 2TL, United Kingdom
  • Clatterbridge Centre for Oncology NHS Foundation Trust
    Wirral, CH634JY, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Apr 2012 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2010
First posted
Jul 21, 2010
Start
Jun 2010
Primary completionActual
Apr 2012
CompletionActual
May 2014
Last update
Nov 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01166542
Lead sponsor
Oncolytics Biotech
Responsible party
Sponsor
First posted
Jul 21, 2010
Start date
Jun 2010
Primary completion
Apr 2012
Completion
May 2014
Last update
Nov 5, 2014

Study contacts

James A Bonner, MD
principal investigator · University of Alabama at Birmingham, Birmingham, AB, US
Kevin Harrington, MBBS MRCP FRCR
principal investigator · The Royal Marsden Hospital, London, UK
Jan Vermorken, MD, PhD
principal investigator · University Hospital, Antwerp, Belgium

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelareorep

Start the discussion